SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).
Maurice Stephan Michel
Honoraria - Astellas Pharma; Bayer; Novartis
Walter Vervenne
No relevant relationships to disclose
Maria de Santis
Consultant or Advisory Role - Astellas Pharma; Bayer; GlaxoSmithKline; Novartis; Pfizer; Pierre Fabre Medicament; Roche
Honoraria - Bayer; Exelixis; GlaxoSmithKline; Novartis; Pfizer; Roche; Sanofi
Research Funding - Pierre Fabre Medicament
Ludwig Fischer von Weikersthal
No relevant relationships to disclose
Peter J. Goebell
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer; Roche
Juergen Lerchenmueller
No relevant relationships to disclose
Uwe Zimmermann
Other Remuneration - DGU German Association of Urology
Monique M.E.M. Bos
No relevant relationships to disclose
Werner Freier
No relevant relationships to disclose
Silke Schirrmacher-Memmel
No relevant relationships to disclose
Michael D. Staehler
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Research Funding - Bayer
Sascha Pahernik
No relevant relationships to disclose
Maartje Los
No relevant relationships to disclose
Marcus Schenck
No relevant relationships to disclose
Anne Flörcken
Honoraria - Bayer; GlaxoSmithKline; Pfizer
Cornelis Van Arkel
No relevant relationships to disclose
Kirsten Hauswald
No relevant relationships to disclose
Martin Indorf
No relevant relationships to disclose
Dana Gottstein
No relevant relationships to disclose
Christian Eichelberg
Consultant or Advisory Role - Bayer (U); GlaxoSmithKline; Novartis; Pfizer
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bayer; GlaxoSmithKline; immatics; Novartis; Pfizer; Wilex
Other Remuneration - Bayer; Novartis; Pfizer